Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Completed · Phase 2

Conditions studied: Asthma

In brief

The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.

Key facts

Study ID

NCT00096616

Run by

Boehringer Ingelheim

People needed

113

Starts

2004-11-01

Last updated by the study team

2013-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient greater than or equal to 18 years of age,
• non-smokers,
• diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
• stable use of Beta agonist
• daily use of inhaled steroids for one year

You may not qualify if…

• Patients with other significant diseases other than asthma, requiring oxygen,
• intubated within 5 years,
• asthma exacerbation within 6 weeks of trial,
• use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
• participating in another interventional trial

Where it is running

• 620 South 20th Street, NHB 104 — Birmingham, Alabama, United States
• Cooper Green Hospital — Birmingham, Alabama, United States
• Southern California Clinical Trials — Lakewood, California, United States
• Boehringer Ingelheim Investigational Site — Palmdale, California, United States
• Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
• Norwalk Hospital — Norwalk, Connecticut, United States
• University of Miami School of Medicine — Miami, Florida, United States
• Boehringer Ingelheim Investigational Site — Panama City, Florida, United States
• Boehringer Ingelheim Investigational Site — Coeur d'Arlene, Idaho, United States
• Boehringer Ingelheim Investigational Site — River Forest, Illinois, United States
• Boehringer Ingelheim Investigational Site — Olathe, Kansas, United States
• LSU MC-Sheveport — Shreveport, Louisiana, United States
• Boehringer Ingelheim Investigational Site — Auburn, Maine, United States
• Johns Hopkins Asthma & Allergy — Baltimore, Maryland, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• Boehringer Ingelheim Investigational Site — Berlin, New Jersey, United States
• Boehringer Ingelheim Investigational Site — Cherry Hill, New Jersey, United States
• North Shore University Hospital — Manhasset, New York, United States
• NYU School of Medicine — New York, New York, United States
• Division of Pulmonary & Critical Care Medicine — Durham, North Carolina, United States
• Wake Forest University, Center for Human Genomics — Winston-Salem, North Carolina, United States
• Penn State University, Hershey Medical Center — Hershey, Pennsylvania, United States
• Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• Spartanburg Medical Research — Spartanburg, South Carolina, United States
• Ben Taul General Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.